相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age
E. B. Walter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
Peter B. Gilbert et al.
SCIENCE (2022)
Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial
Boris Julg et al.
NATURE MEDICINE (2022)
Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants
Yunda Huang et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2022)
Optimizing clinical dosing of combination broadly neutralizing antibodies for HIV prevention
Bryan T. Mayer et al.
PLOS COMPUTATIONAL BIOLOGY (2022)
Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial
Kathryn E. Stephenson et al.
NATURE MEDICINE (2021)
Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials
Yunda Huang et al.
EBIOMEDICINE (2021)
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
David S. Khoury et al.
NATURE MEDICINE (2021)
Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition
L. Corey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Amping up HIV antibodies
Dennis R. Burton
SCIENCE (2021)
Evidence for antibody as a protective correlate for COVID-19 vaccines
Kristen A. Earle et al.
VACCINE (2021)
Broadly Neutralizing Antibodies for HIV Prevention
Shelly T. Karuna et al.
ANNUAL REVIEW OF MEDICINE, VOL 71, 2020 (2020)
The complex challenges of HIV vaccine development require renewed and expanded global commitment
Linda-Gail Bekker et al.
LANCET (2020)
Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention
Kathryn E. Stephenson et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 38 (2020)
Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trials
Daniel B. Reeves et al.
PLOS COMPUTATIONAL BIOLOGY (2020)
Brief Report: Prediction of Serum HIV-1 Neutralization Titers After Passive Administration of VRC01
Yunda Huang et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2020)
Assessing pharmacokinetic marker correlates of outcome, with application to antibody prevention efficacy trials
Peter B. Gilbert et al.
STATISTICS IN MEDICINE (2019)
A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge
Amarendra Pegu et al.
CELL HOST & MICROBE (2019)
Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study
Yehuda Z. Cohen et al.
PLOS ONE (2019)
Interpreting HIV diagnostic histories into infection time estimates: analytical framework and online tool
Eduard Grebe et al.
BMC INFECTIOUS DISEASES (2019)
Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers
Matthias G. Pauthner et al.
IMMUNITY (2019)
A generalizable method for estimating duration of HIV infections using clinical testing history and HIV test results
Christopher D. Pilcher et al.
AIDS (2019)
Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults
Martin R. Gaudinski et al.
PLOS MEDICINE (2018)
Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections
Kshitij Wagh et al.
PLOS PATHOGENS (2018)
Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults
Yunda Huang et al.
MABS (2017)
Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial
Kenneth H. Mayer et al.
PLOS MEDICINE (2017)
Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C
Kshitij Wagh et al.
PLOS PATHOGENS (2016)
Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee
Nathan I. Nicely et al.
EBIOMEDICINE (2015)
Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1
Marcella Sarzotti-Kelsoe et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2014)
HIV-1 Vaccine-Induced C1 and V2 Env-Specific Antibodies Synergize for Increased Antiviral Activities
Justin Pollara et al.
JOURNAL OF VIROLOGY (2014)
Nomenclature for Immune Correlates of Protection After Vaccination
Stanley A. Plotkin et al.
CLINICAL INFECTIOUS DISEASES (2012)
Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial
Barton F. Haynes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Estimating time since infection in early homogeneous HIV-1 samples using a poisson model
Elena E. Giorgi et al.
BMC BIOINFORMATICS (2010)
Correlates of Protection Induced by Vaccination
Stanley A. Plotkin
CLINICAL AND VACCINE IMMUNOLOGY (2010)
Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia
Georgia D. Tomaras et al.
JOURNAL OF VIROLOGY (2008)
Duration of humoral immunity to common viral and vaccine antigens
Ian J. Amanna et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies
M Li et al.
JOURNAL OF VIROLOGY (2005)
On fitting Cox's proportional hazards models to survey data
DY Lin
BIOMETRIKA (2000)
分享论文
